Contrasting I-Mab (NBP) & Its Competitors

I-Mab (NASDAQ:NBP) is one of 865 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare I-Mab to related businesses based on the strength of its earnings, dividends, profitability, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares I-Mab and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
I-Mab Competitors	-9,113.66%	-118.64%	-32.27%

Earnings and Valuation

This table compares I-Mab and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
I-Mab	$3.89 million	-$46.27 million	-4.58
I-Mab Competitors	$675.01 million	$20.71 million	-12.88

I-Mab’s rivals have higher revenue and earnings than I-Mab. I-Mab is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

I-Mab has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, I-Mab’s rivals have a beta of 1.22, meaning that their average share price is 22% more volatile than the S&P 500.

Insider & Institutional Ownership

38.4% of I-Mab shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for I-Mab and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1	0	1	0	2.00
I-Mab Competitors	9068	14544	43752	1426	2.55

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 445.45%. As a group, “Biotechnology” companies have a potential upside of 65.93%. Given I-Mab’s higher possible upside, equities analysts clearly believe I-Mab is more favorable than its rivals.

Summary

I-Mab beats its rivals on 7 of the 13 factors compared.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.